Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant

Reuters

2025/11/20

Nov 2 (Reuters) - Belite Bio Inc ::
*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 02-NOV-202514:00:00.137 GMT

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584259923"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584259923\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584259923?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 00:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584259923","market":"nz","top_or_hot":-1,"title":"Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant","media":"Reuters","content":"<html><body>Nov 2 (Reuters) - <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> Inc <blte.o>::<br/>*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 02-NOV-202514:00:00.137 GMT</blte.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBelite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 00:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 2 (Reuters) - <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> Inc <blte.o>::<br/>*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 02-NOV-202514:00:00.137 GMT</blte.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLTE","symbol_name":"Belite Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6X9sB:1","article_id":"2584259923","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584259923","pubTimestamp":1763569256,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 2 (Reuters) - Belite Bio Inc ::*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLTE":"Belite Bio, Inc.","BK4007":"制药"},"translate_title":"Belite Bio表示英国MHRA同意使用Tinlarebant治疗Stargardt病的有条件营销授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":0.9},"content_text":"Nov 2 (Reuters) - Belite Bio Inc ::*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 02-NOV-202514:00:00.137 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}